News/ News/ R&D Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug Phil Taylor ATTR amyloidosis, CRISPR/Cas9, gene editing, Intellia Therapeutics, rare disease, Regeneron 0 Comment The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the Share X Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug https://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/